Highlights
- •Non-ABCA1 CEC decreased in patients with H. pylori infection compared to controls.
- •ABCA1-mediated CEC decreased in patients with H. pylori compared to controls.
- •Non-ABCA1 and ABCA1-mediated CEC positively associated with apoA-I levels.
- •Non-ABCA1 and ABCA1-mediated CEC negatively associated with hsCRP levels.
Abstract
Background
Gut microorganisms are associated with atherosclerosis and related cardiovascular
disease. Helicobacter pylori (H. pylori) infection is associated with dyslipidemia and inflammation contributing to the progression
of atherosclerosis.
Objective
Several studies have reported reduced HDL-C levels in H. pylori infected patients, but HDL cholesterol efflux capacity (CEC) as the most important
function of HDL has not been evaluated yet.
Methods
This cross-sectional study was conducted with 44 biopsy confirmed H. pylori patients and 43 controls. ABCA1-mediated, non-ABCA1 and total CEC were measured in
ApoB-depleted serum and levels of ApoA-I, ApoB and hsCRP were estimated using ELISA
technique.
Results
Total and ABCA1 mediated-CEC were reduced in patients compared to controls, independent
of age, sex, body mass index and HDL-C (p < 0.001), while non-ABCA1 CEC indicated
no significant change between the groups. In addition, patients showed lower serum
levels of ApoA-I but increased levels of hsCRP when compared to controls. Total CEC
and ABCA1-mediated CEC positively correlated with ApoA-I and HDL-C, furthermore, ABCA1-mediated
CEC as well as ApoA-I inversely correlated with hsCRP.
Conclusion
The results of the present study indicate reduced CECs in H. pylori infected patients, especially ABCA1-mediated CEC which is associated with decreased
ApoA-I and increased inflammation.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical LipidologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis.Gastroenterology. 2017; 153: 420-429
- Meta-analysis of the prevalence of Helicobacter pylori infection among children and adults of Iran.Int J Prev Med. 2016; 7: 48
- Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects.World J Gastroenterol. 2018; 24: 3071-3089
- Exploring the impact of Helicobacter pylori on gut microbiome composition.PloS One. 2019; 14: e0218274
- Cholesterol efflux capacity, macrophage reverse cholesterol transport, and cardioprotective HDL.Curr Opin Lipidol. 2015; 26: 388-393
- Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases.Helicobacter. 2015; 20: 125-132
- Role of Helicobacter pylori infection in pathogenesis of atherosclerosis.World J Cardiol. 2015; 7: 134-143
- Helicobacter pylori: a new cardiovascular risk factor?.Rev Esp Cardiol. 2002; 55: 652-656
- Cardiovascular risk factors in subjects with Helicobacter pylori infection.Helicobacter. 2002; 7: 86-90
- HDL and cardiovascular disease.Lancet. 2014; 384: 618-625
- CETP inhibition: past failures and future hopes.Clin Med Insights Cardiol. 2016; 10: 37-42
- HDL cholesterol efflux capacity and incident cardiovascular events.N Engl J Med. 2014; 371: 2383-2393
- HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.Nat Rev Cardiol. 2011; 8: 222-232
- Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.Lancet Diabetes Endocrinol. 2015; 3: 507-513
- HDL cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease.J Am Coll Cardiol. 2017; 69: 246-247
- Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.Arterioscler Thromb Vasc Biol. 2013; 33: 1696-1705
- Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.N Engl J Med. 2011; 364: 127-135
- Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study.Sci Rep. 2016; 6: 27367
- High-density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity.Prog Cardiovasc Dis. 2015; 58: 32-40
- Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system.Metab Clin Exp. 2006; 55: 980-988
- Antagonism of betulinic acid on LPS-mediated inhibition of ABCA1 and cholesterol efflux through inhibiting nuclear factor-kappaB signaling pathway and miR-33 expression.PLoS One. 2013; 8: e74782
- The acute phase response inhibits reverse cholesterol transport.J Lipid Res. 2010; 51: 682-684
- Inflammation impairs reverse cholesterol transport in vivo.Circulation. 2009; 119: 1135-1145
- Cholesterol, inflammation and innate immunity.Nat Rev Immunol. 2015; 15: 104-116
- Inflammation alters HDL composition and function: implications for HDL-raising therapies.Pharmacol Ther. 2013; 137: 341-351
- Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.J Clin Invest. 2006; 116: 1052-1062
- Helicobacter pylori infection associates with fecal microbiota composition and diversity.Sci Rep. 2019; 9: 20100
- Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.N Engl J Med. 2013; 368: 1575-1584
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature. 2011; 472: 57-63
- Microbiota and HDL metabolism.Curr Opin Lipidol. 2018; 29: 18-23
- Reverse cholesterol transport is increased in germ-free mice-brief report.Arterioscler Thromb Vasc Biol. 2017; 37: 419-422
- Helicobacter pylori genotypes can predict gastric tissue histopathology: a longitudinal study of Iranian patients.J Infect Public Health. 2012; 5: 153-158
- Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis.Sci Rep. 2018; 8: 11691
- High-density lipoprotein particles, cell-cholesterol efflux, and coronary heart disease risk.Arterioscler Thromb Vasc Biol. 2018; 38: 2007-2015
- Helicobacter pylori and inflammation.Curr Pharm Des. 2010; 16: 4225-4236
- An overview of lipid abnormalities in patients with inflammatory bowel disease.Ann Gastroenterol. 2011; 24: 181-187
- TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2.J Lipid Res. 2010; 51: 1407-1415
- Association of Helicobacter pylori infection with elevated serum lipids.Atherosclerosis. 1999; 142: 207-210
- Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol.Am J Cardiol. 2004; 93: 219-220
- Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.Ann Rheum Dis. 2012; 71: 1157-1162
- Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus.Ann Rheum Dis. 2014; 73: 609-615
- Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice.J Clin Invest. 1995; 95: 1587-1594
- Molecular mechanisms of cellular cholesterol efflux.J Biol Chem. 2014; 289: 24020-24029
Article info
Publication history
Published online: November 13, 2020
Accepted:
November 9,
2020
Received in revised form:
November 7,
2020
Received:
March 23,
2020
Footnotes
Conflict of interest: All authors declare no conflict of interest.
Authors contributions: Conception and design: SF, RF and NM; Experiments performance: SMA, NM and RF.; Formal analysis: RF; Supervision: SF, RF and NM; Resources: SF, HG, NM and RF.; Article drafting and revising: GM, MM, SMA, HG and RF; All authors reviewed the manuscript.
Data availability: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Identification
Copyright
© 2020 National Lipid Association. All rights reserved.
